Lilly Stock Drops After New Weight Loss Pill Disappoints

It was a big day for Eli Lilly, but not like the way what people thinking. Investors got a big news about the company’s new weight loss pills and by the end of the day, stock had taken a big fall down. Here’s what actually happened.

Eli Lilly shares fell very fast on Thursday by more than 14% in just one day, what is the reason? The new test of weight loss pills has given a surprising result.

The pill, called orforglipron, was tested for 72 weeks. It helped people lose about 12% of their body weight. This was less than what many people actually expected. A competitor company’s medicine showed about 15% weight loss. Some people in Lilly’s test also felt sick, with side effects like nausea and vomiting.

Lilly did share some good news, too. Sales of its other medicines were strong. One injection drug, Zepbound, which is made $3.38 billion in the second quarter. Another drug, Mounjaro, which is made $5.20 billion. The company also raised its sales forecast for the rest of the year, expecting $60 to $62 billion in total sales, and earnings of $21.75 to $23 per share.

Still, investors focused on the weaker pill results. They worry about Lilly’s chances in the fast-growing weight loss drug market. Because of that, the stock saw its biggest drop in years. At the same time, rival Novo Nordisk’s stock went up after its own pill showed better results.

Now, the big question is what happens next. Lilly is still a strong company, but this result has made investors unhappy. Can the pill improve in the future, or will Lilly have to find another way forward?

For now, the news has left the market watching closely.